Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Heyward

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
JAMA Oncology|October 9, 2025
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology-ReplyJames Heyward, Jodi B Segal
JAMA Internal Medicine|May 5, 2020
Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program-ReplyJames Heyward, Joshua Sharfstein, G Caleb Alexander
BMJ Open|June 14, 2020
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional studyThomas J Moore, James Heyward, Gerard Anderson, et al.
JAMA Network Open|October 12, 2021
Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020Sudipa Sarkar, James Heyward, G Caleb Alexander, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 8, 2021
Lower Use of Biologics for the Treatment of Asthma in Publicly Insured IndividualsAyobami T Akenroye, James Heyward, Corinne Keet, et al.
Journal of Pharmaceutical Sciences|June 17, 2018
The Value of U.S. Pharmacopeial Standards: A Review of the LiteratureJames Heyward, William Padula, Jonothan C Tierce, et al.
Annals of Internal Medicine|November 16, 2020
Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United StatesOmar Mansour, Matthew Tajanlangit, James Heyward, et al.
Plos One|June 6, 2020
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysisJames Heyward, Omar Mansour, Lily Olson, et al.
Pharmaceutical Statistics|May 4, 2021
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populationsJames Heyward, Milena Lolic, Catherine Spong, et al.
Current Epidemiology Reports|October 30, 2024
Weighing risks and benefits in the presence of competing risksCatherine R Lesko, Lauren C Zalla, James Heyward, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
JAMA Oncology|October 9, 2025
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology-ReplyJames Heyward, Jodi B Segal
JAMA Internal Medicine|May 5, 2020
Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program-ReplyJames Heyward, Joshua Sharfstein, G Caleb Alexander
BMJ Open|June 14, 2020
Variation in the estimated costs of pivotal clinical benefit trials supporting the US approval of new therapeutic agents, 2015-2017: a cross-sectional studyThomas J Moore, James Heyward, Gerard Anderson, et al.
JAMA Network Open|October 12, 2021
Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020Sudipa Sarkar, James Heyward, G Caleb Alexander, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 8, 2021
Lower Use of Biologics for the Treatment of Asthma in Publicly Insured IndividualsAyobami T Akenroye, James Heyward, Corinne Keet, et al.
Journal of Pharmaceutical Sciences|June 17, 2018
The Value of U.S. Pharmacopeial Standards: A Review of the LiteratureJames Heyward, William Padula, Jonothan C Tierce, et al.
Annals of Internal Medicine|November 16, 2020
Telemedicine and Office-Based Care for Behavioral and Psychiatric Conditions During the COVID-19 Pandemic in the United StatesOmar Mansour, Matthew Tajanlangit, James Heyward, et al.
Plos One|June 6, 2020
Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysisJames Heyward, Omar Mansour, Lily Olson, et al.
Pharmaceutical Statistics|May 4, 2021
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Keynote and panel discussion on communicating heterogeneous treatment effects across populationsJames Heyward, Milena Lolic, Catherine Spong, et al.
Current Epidemiology Reports|October 30, 2024
Weighing risks and benefits in the presence of competing risksCatherine R Lesko, Lauren C Zalla, James Heyward, et al.
Pageof 3